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Abstract
Background: Curcumin is the major yellow pigment extracted from turmeric, a commonly-used
spice in India and Southeast Asia that has broad anticarcinogenic and cancer chemopreventive
potential. However, few systematic studies of curcumin's pharmacology and toxicology in humans
have been performed.
Methods: A dose escalation study was conducted to determine the maximum tolerated dose and
safety of a single dose of standardized powder extract, uniformly milled curcumin (C3 Complex™,
Sabinsa Corporation). Healthy volunteers were administered escalating doses from 500 to 12,000
mg.
Results: Seven of twenty-four subjects (30%) experienced only minimal toxicity that did not
appear to be dose-related. No curcumin was detected in the serum of subjects administered 500,
1,000, 2,000, 4,000, 6,000 or 8,000 mg. Low levels of curcumin were detected in two subjects
administered 10,000 or 12,000 mg.
Conclusion: The tolerance of curcumin in high single oral doses appears to be excellent. Given
that achieving systemic bioavailability of curcumin or its metabolites may not be essential for
colorectal cancer chemoprevention, these findings warrant further investigation for its utility as a
long-term chemopreventive agent.
Background
Curcumin is the major yellow pigment extracted from tur-
meric, a commonly-used spice derived from the rhizome
of the herb Curcuma longa. In India and Southeast Asia, it
has long been used as a treatment for inflammation, skin
wounds and tumors [1,2]. The clinical efficacy of curcu-
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tive potential is demonstrated by the anticarcinogenic
effects in cell culture and animal models of skin, breast,
and gastrointestinal carcinogenesis [3-6].
Curcumin appears to be safe in both large and small ani-
mal models, but few systematic studies of curcumin's
pharmacology and toxicology in humans have been per-
formed [7-9]. Minimal toxicity of doses up to 8,000 mg
have been described in humans [7,8] and to date, no max-
imum tolerated dose has been defined. Despite curcu-
min's apparent poor bioavailability [7,8], peak plasma
concentration has been identified 1 to 2 hours after single
dose oral administration of 4,000 mg and higher [7].
Based on this information, we performed a dose escala-
tion study to determine the maximum tolerated dose,
safety profile, and resultant serum concentration of a sin-
gle dose of standardized powder extract obtained from
Alleppey finger turmeric (C3 Complex™, Sabinsa Corpora-
tion).
Methods
Study population and design
Eligible participants were male and female volunteers, 18
years of age or older with normal organ function who had
not consumed any curcumin-rich foods to their knowl-
edge within the previous 14 days. Subjects completed a
food checklist to verify that they were not consuming cur-
cumin-rich foods. After written informed consent was
obtained, three subjects were entered consecutively at
dose levels from 500 to 12,000 mg. Subjects took the dose
with 8 fl. oz. of water followed by a standard meal con-
taining dietary fat (providing 34 g or 42 g fat, per 2200
kcal/day or 2500 kcal/day meal plan, respectively).
Safety was assessed for 72 hours following the curcumin
dose. Toxicities were graded based on National Cancer
Institute, Common Toxicity Criteria version 2.0 [10]. The
maximum tolerated dose was the highest dose which did
not cause escalation to cease.
The study protocol and the comprehensive written
informed consent used in this study protocol were
reviewed and approved by the University of Michigan
Human Subject Review Board prior to the start of the
study. This review panel is certified under the Federal
Wide Assurance Of Protection For Human Subjects (FWA
00004969) that expires June 12, 2006. The investigators
followed with annual reports, renewals, and approval
throughout the duration of the study including the analy-
sis of the data.
Study drug
Curcumin was provided in a capsule form as a standard-
ized powder extract obtained from Alleppey finger tur-
meric (C3 Complex™, Sabinsa Corporation). It contains a
minimum 95% concentration of three curcuminoids: cur-
cumin, bisdemethoxycurcumin, and demethoxycurcu-
min.
Serum curcumin analysis
Blood specimens from all subjects on the escalation phase
were obtained just prior to dosing, and 1, 2 and 4 hours
after completing dosing at each dose level tested. The sam-
ples were assayed using our published methods [11].
Briefly, a total of 400 µL plasma were extracted with 500
µL of ethyl acetate/methanol reagent. The recovered solu-
tion was dried under a stream of nitrogen gas, resus-
pended in 200 µL of mobile phase reagent, and assayed
using high performance liquid chromatography (HLPC).
HPLC conditions were: isocratic mobile phase of ace-
tonitrile/methanol/water/acetic acid (40:23:36:1, v/v/v/
v), at a flow rate of 1.0 ml/min; column: Waters Symme-
tryShield, 3.9 × 150 mm, 5 µm; UV detection at 262 nm.
Curcumin detection was found to be linear within a range
of 0.2–7.0 µg/mL, with a limit of detection of 0.031 µg/
mL. Between run coefficient of variation (CV) was <7.5.
Results
Thirty-four participants signed informed consents.
Twenty-four completed the trial and were eligible for this
analysis. Of the twenty-four participants analyzed in this
trial, thirteen men and eleven women with mean age of 34
Table 1: All adverse events by dose levels
Dose levela Type No. of events Toxicity gradeb
1000 mg Diarrhea 1 1
4000 mg Headache 1 1
8000 mg Rash 1 1
Yellow Stool 1 1
10000 mg Yellow Stool 1 1
Headache 1 1
12000 mg Diarrhea 1 1
a Total of 3 subjects at each dose level
b National Cancer Institute, Common Toxicity Criteria v.2.0 [10]Page 2 of 4
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racial distribution was 18 Caucasians and 6 African-Amer-
icans. Seven adverse events occurred and all were grade 1
as summarized in Table 1. No toxicity appeared to be dose
related.
No curcumin was detected in serum of participants
administered 500, 1,000, 2,000, 4,000, 6,000 or 8,000
mg. Table 2 shows the concentrations of curcumin in two
subjects (1 taking 10,000 mg, and 1 taking 12,000 mg).
No plasma concentrations of curcumin were detected in
the remaining subjects at the 10,000 or 12,000 mg dose
levels.
Discussion
Curcumin has broad spectrum chemopreventive activity
in preclinical studies and appears to be safe in animal and
human studies [3,12,13]. For chemopreventive interven-
tions to be successful, they must be provided in doses that
are effective, but be nearly free of toxicities. Several studies
have demonstrated minimal toxicity with moderate doses
of curcumin given in various formulations. Soni and Kut-
tan [14] administered 500 mg capsules of a 98% pure cur-
cumin formulation to 10 volunteers daily for 7 days and
reported no clinical toxicity. Two trials evaluating the effi-
cacy of turmeric or curcumin for the treatment of arthritis
or postoperative inflammation found that doses of 1,200
to 2,100 mg of curcumin per day for 2–6 weeks were with-
out adverse effects [15,16]. Cheng et al [7] reported no
treatment-related toxicity up to 8,000 mg/day using a
99.3% pure curcumin tablet (500 mg of curcumin in each
tablet). However, doses up to 12,000 mg were unaccepta-
ble to patients due to the bulky volume of the tablets. In
the present study, we recognized minimal toxicity up to
12,000 mg in a single dose of standardized powder extract
(C3 Complex™, Sabinsa Corporation) obtained from Allep-
pey finger turmeric (Table 1). Thus, to our knowledge, no
maximum tolerated dose has been identified in humans,
although successful administration may be affected by dif-
ferences in drug formulation.
Low serum levels of curcumin after single dose adminis-
tration is consistent with the previously reported pharma-
cokinetic studies in animals and humans [7-9,17-20].
Wahlstrom et al [18] administered 1 g/kg to Sprague-
Dawley rats and found 65–85% of the dose excreted
unchanged in the feces with negligible amounts in the
urine. Studies with deuterium and tritium-labeled curcu-
min given orally to rats resulted in most of the detectable
radioactivity in the feces [18,20]. Negligible amounts of
radioactivity were detectable in plasma when smaller
doses of [3H]-curcumin were administered [20]. Sharma
et al [8] administered Curcuma extract 440 to 2,200 mg/
day (36 to 180 mg of curcumin) for up to 29 days to
patients with advanced colorectal cancer and failed to
detect curcumin or its metabolites in blood or urine.
Serum concentrations may be dependent on the dose that
is administered. Cheng et al [7] determined the concentra-
tion of curcumin by HPLC in 25 subjects with high risk
cancer lesions. The peak serum concentration after 4,000,
6,000, and 8,000 mg were 0.51 ± 0.11 µM, 0.64 ± 0.06
µM, and 1.77 ± 1.87 µM, respectively, but doses below
4,000 mg were barely detectable. These findings are con-
sistent with the present study, in which low levels of cur-
cumin were measured only at doses ≥8,000 mg (Table 2).
Low serum levels of curcumin may be due in part to the
extensive intestinal and hepatic metabolic biotransforma-
tion. Preclinical work has demonstrated that avid sulfa-
tion, glucuronidation, and reduction of curcumin occurs
in the gastrointestinal tracts of rats and humans [19,21-
23]. A challenge for future chemopreventive strategies lies
in the conflicting evidence of the biological effects of the
resultant metabolites. For example, lymphocytic glutath-
ione S-transferase activity, a potential surrogate biomarker
of curcumin activity, was significantly decreased in
patients taking 440 mg/day despite the lack of measurable
serum curcumin [8]. This finding suggests that curcumin-
oid metabolites, which may not have been detected,
resulted in a systemic biological effect. In contrast, exper-
iments by Ireson et al [24] suggest that the metabolism of
curcumin generates species with reduced ability to inhibit
COX-2 expression compared to the parent compound.
Given these conflicting data, the poor bioavailability of
curcumin, and the fact that the gastrointestinal tract is
exposed to the greatest concentration of unmetabolized
curcumin, colorectal cancer chemoprevention is the most
attractive area for future efforts.
To further elucidate the cause of low serum curcumin lev-
els after large dose consumption in the present study, the
curcumin capsules were analyzed. Each capsule was found
to be 75% curcumin, 23% demethoxycurcumin and 2%
bisdemethoxycurcumin, which is consistent with other
commercial curcuminoid products. However, the curcu-
min activity as measured by HPLC area count for a
Table 2: Serum curcumin levels in ng/ml for two subjects
Dose Baseline One hour Two hour Four hour
10000 mg approx. 6.0 30.4 39.5 50.5
12000 mg approx. trace 29.7 57.6 51.2Page 3 of 4
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equivalent weighed portion of a previously supplied, pure
curcumin powder (unpublished data). Thus, curcumin
bioavailability in humans and biologic activity might dif-
fer based upon the formulation used.
Conclusion
The tolerance of curcumin (C3 Complex™, Sabinsa Corpo-
ration) in single oral doses up to 12,000 mg appears to be
excellent and warrants further investigation for its utility
as a long-term chemopreventive intervention. Despite the
lack of a defined maximum tolerated dose, the more
important issue in chemopreventive investigation lies in
determining the biologically effective dose. Future clinical
investigation is required to determine such a dose. Poor
bioavailability from the gut limits the systemic cancer pre-
ventive activity of curcumin and higher doses, as used in
this study, may be required to overcome intestinal metab-
olism and achieve systemic effects. However, further
investigation to determine the direct effects of curcumin
on colonic mucosa are warranted to adequately assess the
efficacy of curcumin as a colorectal cancer chemopreven-
tive agent.
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